{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:40:52Z","timestamp":1790394052056,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"BC Centre for Disease Control and the Canadian Institutes of Health Research","award":["NHC-142832"],"award-info":[{"award-number":["NHC-142832"]}]},{"name":"BC Centre for Disease Control and the Canadian Institutes of Health Research","award":["PHE-141773"],"award-info":[{"award-number":["PHE-141773"]}]},{"name":"Roche Molecular Systems, Siemens Healthcare Diagnostics, and Hologic"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.drugpo.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T12:02:57Z","timestamp":1561032177000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada"],"prefix":"10.1016","volume":"72","author":[{"given":"Mel","family":"Krajden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-120X","authenticated-orcid":false,"given":"Darrel A.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2486-4781","authenticated-orcid":false,"given":"Zahid A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Darvishian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-393X","authenticated-orcid":false,"given":"Jane A.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tyndall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-719X","authenticated-orcid":false,"given":"Naveed Z.","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.drugpo.2019.06.003_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-018-3110-0","article-title":"Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993\u20132012","volume":"18","author":"Alavi","year":"2018","journal-title":"BMC Infectious Diseases"},{"issue":"8","key":"10.1016\/j.drugpo.2019.06.003_bib0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.003_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0025","series-title":"Reportable diseases dashboard","author":"BC Centre for Disease Control","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0030","series-title":"Fentanyl-detected illicit drug overdose deaths","author":"BC Coroners Service","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0035","series-title":"Issues to consider when analyzing ICD-10 coded data on drug poisoning (Overdose) deaths","author":"Centers for Disease Control and Prevention","year":"2018"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.003_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Medical Care"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"8","key":"10.1016\/j.drugpo.2019.06.003_bib0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jvh.12529","article-title":"New treatments for hepatitis C virus (HCV): Scope for preventing liver disease and HCV transmission in England","volume":"23","author":"Harris","year":"2016","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.003_bib0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.26623","article-title":"Eradication of hepatitis C infection: The importance of targeting people who inject drugs","volume":"59","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.drugpo.2019.06.003_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: Results in real life","volume":"38","author":"H\u00e9zode","year":"2018","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.29419","article-title":"The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study","volume":"67","author":"Innes","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.003_bib0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/jvh.12650","article-title":"Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort","volume":"24","author":"Islam","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","article-title":"Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada","volume":"66","author":"Janjua","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2019.06.003_bib0095","first-page":"91A","article-title":"The impact of HCV sustained virologic response from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study","volume":"68","author":"Janjua","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150176","article-title":"Assessing hepatitis C burden and treatment effectiveness through the british Columbia hepatitis testers cohort (BC-HTC): Design and characteristics of linked and unlinked participants","volume":"11","author":"Janjua","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12879-016-1683-z","article-title":"Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort","volume":"16","author":"Janjua","year":"2016","journal-title":"BMC Infectious Diseases"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.003_bib0110","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1473-3099(16)00124-9","article-title":"The spread of hepatitis C virus genotype 1a in North America: A retrospective phylogenetic study","volume":"16","author":"Joy","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2019.06.003_bib0115","first-page":"913A","article-title":"Impact of HCV sustained virologic response on liver- and drug-related mortality in a large population based cohort","volume":"68","author":"Krajden","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.003_bib0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.idc.2018.02.002","article-title":"Long-term liver disease, treatment, and mortality outcomes among 17,000 persons diagnosed with chronic hepatitis C virus infection: Current chronic hepatitis cohort study status and review of findings","volume":"32","author":"Moorman","year":"2018","journal-title":"Infectious Disease Clinics of North America"},{"issue":"10100","key":"10.1016\/j.drugpo.2019.06.003_bib0125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.003_bib0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.24095\/hpcdp.29.4.05","article-title":"A deprivation index for health planning in Canada","volume":"29","author":"Pampalon","year":"2009","journal-title":"Chronic Disease Prevention in Canada"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/FTD.0000000000000465","article-title":"Acute intoxications and fatalities from illicit fentanyl and analogues: An update","volume":"40","author":"Pichini","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0140","series-title":"National report: Apparent opioid-related deaths in Canada (released September 2018)","author":"Public Health Agency of Canada","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0145","series-title":"Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada","author":"Remis","year":"2007"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1007644","article-title":"Nucleic acid testing to detect HBV infection in blood donors","volume":"364","author":"Stramer","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999\u20132016: Observational study","author":"Tapper","year":"2018","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.003_bib0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study","volume":"2","author":"The Polaris Observatory","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.003_bib0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.drugpo.2019.06.003_bib0170","doi-asserted-by":"crossref","first-page":"429","DOI":"10.14745\/ccdr.v40i19a02","article-title":"Estimated prevalence of Hepatitis C virus infection in Canada, 2011","volume":"40","author":"Trubnikov","year":"2014","journal-title":"Canada Communicable Disease Report"},{"issue":"9","key":"10.1016\/j.drugpo.2019.06.003_bib0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: Trends in emergency department visits for suspected opioid overdoses \u2014 United States, July 2016\u2013September 2017","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"Morbidity and Mortality Weekly Report: MMWR"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0180","series-title":"International statistical classification of diseases and related health problems, 10th revision","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0185","series-title":"Combating hepatitis B and C to reach elimination by 2030","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0190","series-title":"Fact sheets: Hepatitis C","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.003_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2458-13-291","article-title":"Mortality among British Columbians testing for hepatitis C antibody","volume":"13","author":"Yu","year":"2013","journal-title":"BMC Public Health"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T08:46:54Z","timestamp":1663750014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"alternative-id":["S0955395919301586"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.003","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}